Fuller & Thaler Asset Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $685K | Sell |
107,370
-40,110
| -27% | -$256K | ﹤0.01% | 416 |
|
|
2025
Q1 | $717K | Sell |
147,480
-8,585
| -6% | -$41.7K | ﹤0.01% | 418 |
|
|
2024
Q4 | $1.49M | Buy |
156,065
+170
| +0.1% | +$1.63K | 0.01% | 387 |
|
|
2024
Q3 | $1.3M | Sell |
155,895
-583,930
| -79% | -$4.88M | 0.01% | 373 |
|
|
2024
Q2 | $5.05M | Sell |
739,825
-35,800
| -5% | -$244K | 0.02% | 314 |
|
|
2024
Q1 | $1.96M | Buy |
+775,625
| New | +$1.96M | 0.01% | 379 |
|
|
2021
Q2 | – | Sell |
-503,405
| Closed | -$46.8M | – | 536 |
|
|
2021
Q1 | $46.8M | Buy |
503,405
+216,671
| +76% | +$20.1M | 0.33% | 101 |
|
|
2020
Q4 | $25.7M | Buy |
286,734
+95,599
| +50% | +$8.57M | 0.24% | 120 |
|
|
2020
Q3 | $19.8M | Buy |
+191,135
| New | +$19.8M | 0.25% | 114 |
|
|
2019
Q2 | – | Sell |
-200,450
| Closed | -$10.1M | – | 466 |
|
|
2019
Q1 | $10.1M | Buy |
200,450
+6,683
| +3% | +$338K | 0.13% | 145 |
|
|
2018
Q4 | $11.5M | Sell |
193,767
-13,388
| -6% | -$794K | 0.17% | 126 |
|
|
2018
Q3 | $13.6M | Sell |
207,155
-8,879
| -4% | -$585K | 0.14% | 136 |
|
|
2018
Q2 | $10.9M | Buy |
216,034
+794
| +0.4% | +$40.1K | 0.12% | 142 |
|
|
2018
Q1 | $11.3M | Sell |
215,240
-6,400
| -3% | -$337K | 0.13% | 127 |
|
|
2017
Q4 | $10.3M | Buy |
+221,640
| New | +$10.3M | 0.12% | 122 |
|